skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

81 Total results for product and free and sample content found

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 16 Oct 2019

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell and gene therapy Drug development landscape

Scrip

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

By Andrew McConaghie 16 Oct 2019

Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.

Topic Research BioPharmaceutical

Scrip

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

By Mandy Jackson 16 Oct 2019

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Topic Cell and gene therapy

Scrip

Woodford Debacle Is A Test Of UK Biotech's Resilience

By Andrew McConaghie 16 Oct 2019

Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

Topic BioPharmaceutical Company analysis

Scrip

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

By Alex Shimmings 14 Oct 2019

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Topic Cancer Drug development landscape Research

Scrip

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

By Brian Yang 14 Oct 2019

Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.

Topic Deal trends Strategy

Datamonitor Healthcare

mHealth and Research in Oncology

27 Sep 2019

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

Datamonitor Healthcare, Biomedtracker

Gene therapy manufacturers

26 Sep 2019

Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

Biomedtracker, Datamonitor Healthcare

Deconstructing the KRAS+ market opportunity

By Daniel Chancellor 06 Aug 2019

With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

Topic BioPharmaceutical Drug review

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: